Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model-Reference-Cited by-同舟云学术

Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model

Published:2016-03 Issue:2 Volume:372 Page:179-186
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Iyer Radhika,Wehrmann Lea,Golden Rebecca L.^ORCID,Naraparaju Koumudi,Croucher Jamie L.,MacFarland Suzanne P.,Guan Peng,Kolla Venkatadri,Wei Ge,Cam Nicholas,Li Gang^ORCID,Hornby Zachary,Brodeur Garrett M.^ORCID

Funder

NIH

Ignyta, Inc.

Alex's Lemonade Stand Foundation

Audrey E. Evans Endowed Chair

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference89 articles.

1. Cell signaling by receptor tyrosine kinases;Lemmon;Cell,2010

2. Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin;McDonell;Hum. Mol. Genet,2015

3. Therapeutic targets for neuroblastomas;Brodeur;Expert Opin. Ther. Targets,2014

4. Trk receptor expression and inhibition in neuroblastomas;Brodeur;Clin. Cancer Res,2009

5. On Trk – the TrkB signal transduction pathway is an increasingly important target in cancer biology;Thiele;Clin. Cancer Res,2009

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma;Cancers;2024-08-17

2. Entrectinib in the treatment of ROS1-positive lung cancer;Meditsinskiy sovet = Medical Council;2024-01-17

3. Design and synthesis of fluorine aromatic scaffolds containing drugs approved by the US FDA from 2002 to 2022;Results in Chemistry;2024-01

4. Narrative review: precision medicine applications in neuroblastoma—current status and future prospects;Translational Pediatrics;2024-01

5. Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review;Current Topics in Medicinal Chemistry;2024-01